CAS 1206163-45-2

GLPG-0778

CAS : 1206163-45-2

Formule : C₂₂H₂₃N₅O₂

Degré de pureté : %

Couleur et forme : Solid

Masse moléculaire : 389.4503

Ref: IN-DA008TN5

Solcitinib

CAS : 1206163-45-2

Solcitinib

Degré de pureté : ≥98%

Masse moléculaire : 389.45g/mol

Ref: 54-BUP13512

N-(5-(4-(3,3-Dimethylazetidine-1-Carbonyl)Phenyl)-[1,2,4]Triazolo[1,5-A]Pyridin-2-Yl)Cyclopropanecarboxamide

CAS : 1206163-45-2

N-(5-(4-(3,3-Dimethylazetidine-1-Carbonyl)Phenyl)-[1,2,4]Triazolo[1,5-A]Pyridin-2-Yl)Cyclopropanecarboxamide

Degré de pureté : 98%

Masse moléculaire : 389.45g/mol

Ref: 54-OR1024363

Solcitinib

CAS : 1206163-45-2

Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.

Formule : C₂₂H₂₃N₅O₂

Degré de pureté : 99.61% - 99.82%

Couleur et forme : Solid

Masse moléculaire : 389.45

Ref: TM-T3620

N-(5-(4-(3,3-Dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide

CAS : 1206163-45-2

Formule : C₂₂H₂₃N₅O₂

Degré de pureté : 98+%

Masse moléculaire : 389.459

Ref: 10-F497231

Solcitinib

CAS : 1206163-45-2

Solcitinib is a Jak1 inhibitor that is being evaluated for its potential to treat cancer. The drug inhibits the activity of the Janus kinase 1 (JAK1) enzyme, which is involved in signaling pathways that are important for cell growth and survival. Solcitinib has been shown to inhibit tumor growth in animal models of cancer and has been shown to be well-tolerated in humans with advanced solid tumors who have previously received treatment with other anti-cancer agents. In addition, solcitinib has been shown to reduce inflammation and improve immune function in animal models of inflammatory bowel disease and bowel disease. This drug may also be effective against autoimmune diseases such as alopecia areata or inflammatory bowel disease.

Formule : C₂₂H₂₃N₅O₂

Degré de pureté : Min. 95%

Masse moléculaire : 389.45 g/mol

Ref: 3D-GYB16345